Skip to main content

Photoactivatable Drug Releasing Implants

Project description

Blue light-controlled drug-releasing implants

The inability to use high-energy blue/UV light as the signal for light-triggered on-demand drug delivery is due to a formidable physiological barrier. This makes red light the only alternative. However, red light has intrinsically lower energy and limited value in photochemical reactions because the photocleavage of covalent bonds typically requires UV light. The EU-funded PADRE project will use blue/UV light to trigger and precisely control on-demand drug-releasing implants. The project will use light generated through photon upconversion or integrated light sources. The first method will allow pioneering, effective red-to-blue/UV triplet-triplet annihilation upconversion in a hydrogel environment. The second will enable light generation by a co-implanted light source.

Call for proposal

ERC-2020-COG
See other projects for this call

Host institution

HELSINGIN YLIOPISTO
Address
Yliopistonkatu 3
00014 Helsingin Yliopisto
Finland
Activity type
Higher or Secondary Education Establishments
EU contribution
€ 1 155 415

Beneficiaries (2)

HELSINGIN YLIOPISTO
Finland
EU contribution
€ 1 155 415
Address
Yliopistonkatu 3
00014 Helsingin Yliopisto
Activity type
Higher or Secondary Education Establishments
TAMPEREEN KORKEAKOULUSAATIO SR
Finland
EU contribution
€ 807 062
Address
Kalevantie 4
33100 Tampere
Activity type
Higher or Secondary Education Establishments